Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:EUROHELICAN—The first helicobacter pylori screen-and-treat population-based study in young adults in Europe
Authors:ID Tepeš, Bojan (Author)
ID Kofol-Bric, Tatjana (Author)
ID Završnik, Jernej (Author)
ID Oblak, Mitja (Author)
ID Kralj, Marcel (Author)
ID Polajžer, Alja (Author)
ID Blažun Vošner, Helena (Author)
ID Maguša Lorber, Nataša (Author)
ID Park, Jin Young (Author)
ID Matysiak‐Budnik, Tamara (Author)
Files:URL URL - Source URL, visit https://onlinelibrary.wiley.com/doi/10.1002/ueg2.70196?msockid=1ab7f71cbeb166d72f07e380bfc96748
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo NIJZ - National Institute of Public Health
Abstract:Background Most gastric cancer cases are attributable to chronic Helicobacter pylori (H. pylori) infection and can theoretically be prevented. Objective In the EUROHELICAN project, we aimed to assess the feasibility, acceptability, effectiveness, and adverse events of a Helicobacter pylori screen-and-treat program in the 30–34-year age group for the first time in Europe. Design The study was conducted in the Community Healthcare Center dr. Adolf Drolc Maribor, following the methodology prepared by the National Institute of Public Health. We invited asymptomatic individuals aged 30–34 to be tested for H. pylori IgG antibodies; positive results were confirmed by urea breath test (UBT). Results 2102 participants accepted the invitation. The response rate was 24.4% (95% CI: 23.2–25.5), which was higher in women—28.1% (95% CI: 26.4–29.8) than in men—20.5% (95% CI: 0.19.0–22.1, p < 0.001). The serological prevalence of H. pylori infection was 14.2% (95% CI: 12.7–15.9). A confirmatory urea breath test (UBT) was positive in 83.7% of serology-positive patients. The eradication rate of 14-day bismuth-based quadruple therapy (esomeprazole 40 mg BID, amoxicillin 500 mg, metronidazole 400 mg and bismuth oxide 120 mg, all QID) was 94.7% (95% CI: 89.5–97.9). Adverse events (AEs) during treatment were reported more frequently in women (38.8%, 95% CI: 28.1–50.3) than in men (21.5%, 95% CI: 12.3–33.5; p < 0.05). Conclusion H. pylori screening and-treat program in 30–34 age group in Slovenia is feasible; H. pylori treatment is very effective with acceptable rate of AEs. Different approaches to raising public awareness are needed to increase participation rates.
Publication version:Version of Record
Submitted for review:24.12.2025
Article acceptance date:05.02.2026
Publication date:26.02.2026
Year of publishing:2026
Number of pages:str. 1-10
Numbering:Vol. 14, iss. 2, [article no.] e70196
PID:20.500.12556/DiRROS-28393 New window
UDC:616.3
ISSN on article:2050-6414
DOI:10.1002/ueg2.70196 New window
COBISS.SI-ID:271914499 New window
Note:Nasl. z nasl. zaslona; Opis z dne 17. 3. 2026;
Publication date in DiRROS:17.03.2026
Views:20
Downloads:13
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:United European Gastroenterology journal
Shortened title:United European Gastroenterol. j.
Publisher:SAGE Publications
ISSN:2050-6414
COBISS.SI-ID:519824153 New window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Title:The first helicobacter pylori screen-and-treat population-based study in young adults in europe
Keywords:gastric cancer, long term effects, prevention, screen‐and‐treat


Back